| 摘要 |
The present invention concerns a product containing Sandostatin(R) LAR(R) at 40 mg/28 days or pasireotide and either a dopamine-agonist, preferably cabergoline, or a growth hormone receptor antagonist, preferably pegvisomant, as a combined preparation for simultaneous, separate or sequential use in acromegalic therapy. In particular, this therapy is useful for treating acromegalic patients not achieving biochemical normalization after at least six-month treatment using at least one somatostatin analogue at conventional regimen.
|
